Regulation of adenylyl cyclase activity by beta-adrenergic agonists in a desensitization-resistant mutant cell line.
Mutant clones resistant to ACTH-induced desensitization of adenylyl cyclase (Y1DR) were previously isolated from the Y1 mouse adrenocortical tumor cell line. In this study, both parental Y1 cells (Y1DS) and a Y1DR mutant were transfected with a gene encoding the mouse beta 2-adrenergic receptor, and transfectants isolated from both Y1DS and Y1DR cells were shown to express beta 2-adrenergic receptors. These transfectants responded to the beta-adrenergic agonist isoproterenol with increases in adenylyl cyclase activity and steroidogenesis and changes in cell shape. The transfectants were analyzed to determine whether the Y1DR mutation was specific for ACTH-induced desensitization of adenylyl cyclase or also affected desensitization of adenylyl cyclase via the beta 2-adrenergic receptor. Treatment of intact Y1DS transfectants with isoproterenol caused a rapid desensitization of the adenylyl cyclase system to further stimulation by the beta-adrenergic agonist. Treatment of intact cells with isoproterenol did not affect ACTH-stimulated adenylyl cyclase activity, indicating that desensitization was agonist specific or homologous. Y1DR transfectants were resistant to the desensitizing effects of isoproterenol in intact cells as well as in cell homogenates. These results indicate that the mutation in Y1DR transfectants affects a component that is common to the pathways of isoproterenol-induced desensitization and ACTH-induced desensitization of adenylyl cyclase. As determined using the hydrophilic beta-receptor antagonist CGP-12177, isoproterenol caused a rapid sequestration of cell surface receptors in both Y1DS and Y1DR transfectants. From these results we infer that the DR phenotype does not arise from mutations affecting receptor sequestration and that receptor number does not limit the response to isoproterenol in these transfectants.
Olson
M F
MF
Banting and Best Department of Medical Research Department of Pharmacology, University of Toronto, Ontario, Canada.
Tsao
J
J
Pon
D J
DJ
Schimmer
B P
BP
D000262:Adenylyl Cyclases / Q000378:metabolism*; D000306:Adrenal Cortex Neoplasms; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000818:Animals; D015870:Gene Expression; D020120:Iodocyanopindolol; D007545:Isoproterenol / Q000494:pharmacology; D051379:Mice; D009154:Mutation; D010869:Pindolol / Q000031:analogs & derivatives / Q000378:metabolism; D010957:Plasmids; D011412:Propanolamines / Q000378:metabolism; D011943:Receptors, Adrenergic, beta / Q000235:genetics / Q000502:physiology*; D012969:Sodium Fluoride / Q000494:pharmacology; D014162:Transfection; D014407:Tumor Cells, Cultured
D011412:Propanolamines; D011943:Receptors, Adrenergic, beta; D020120:Iodocyanopindolol; D012969:Sodium Fluoride; D000324:Adrenocorticotropic Hormone; D010869:Pindolol; D000262:Adenylyl Cyclases; D007545:Isoproterenol; C033394:CGP 12177